Dyne Therapeutics (NASDAQ:DYN – Free Report) had its target price reduced by HC Wainwright from $55.00 to $46.00 in a research report report published on Friday morning,Benzinga reports.
Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned for Mid-2025 to Support Submission for U.S. Accelerated Approval - - Full Enrollment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback